PYC Therapeutics Limited (PYC.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
As of 10:56AM AEST. Market open.
| Previous close | 0.1000 |
| Open | 0.1050 |
| Bid | 0.1100 x 42340100 |
| Ask | 0.1150 x 21464600 |
| Day's range | 0.1050 - 0.1100 |
| 52-week range | 0.0500 - 0.1150 |
| Volume | |
| Avg. volume | 1,822,544 |
| Market cap | 513.269M |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | 23 July 2024 - 28 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.35 |
Simply Wall St.Here's Why We're Not Too Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- Simply Wall St.
Owning 57% in PYC Therapeutics Limited (ASX:PYC) means that insiders are heavily invested in the company's future
Key Insights Insiders appear to have a vested interest in PYC Therapeutics' growth, as seen by their sizeable ownership...
PR NewswirePYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE
PYC Therapeutics today announces the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication[8].
© 2024 Yahoo. All rights reserved.